Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
Exagen (NASDAQ: XGN), a leader in autoimmune testing, has scheduled its Q2 2025 financial results announcement for July 29, 2025, before market opening. The company will host a conference call at 8:30 AM ET featuring CEO John Aballi and CFO Jeff Black.
Investors can join via phone (201-389-0918 U.S. or +1-877-407-0890 international) or through the webcast link on Exagen's investor relations website. A replay will be available until August 12, 2025, accessible by phone using passcode 13753132 or through the company website.
Exagen (NASDAQ: XGN), leader nei test per malattie autoimmuni, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 29 luglio 2025, prima dell'apertura del mercato. La società terrà una conference call alle 8:30 AM ET con il CEO John Aballi e il CFO Jeff Black.
Gli investitori potranno partecipare telefonicamente (201-389-0918 per gli USA o +1-877-407-0890 per l'internazionale) oppure tramite il link webcast sul sito web delle relazioni con gli investitori di Exagen. Una registrazione sarà disponibile fino al 12 agosto 2025, accessibile telefonicamente con il codice 13753132 o tramite il sito aziendale.
Exagen (NASDAQ: XGN), líder en pruebas para enfermedades autoinmunes, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 29 de julio de 2025, antes de la apertura del mercado. La empresa realizará una llamada conferencia a las 8:30 AM ET con el CEO John Aballi y el CFO Jeff Black.
Los inversores pueden unirse por teléfono (201-389-0918 en EE.UU. o +1-877-407-0890 internacional) o mediante el enlace de la transmisión en vivo en el sitio web de relaciones con inversores de Exagen. Una repetición estará disponible hasta el 12 de agosto de 2025, accesible por teléfono usando el código 13753132 o a través del sitio web de la compañía.
Exagen (NASDAQ: XGN)은 자가면역 검사 분야의 선두주자로, 2025년 2분기 재무 결과 발표를 2025년 7월 29일 시장 개장 전으로 예정했습니다. 회사는 CEO John Aballi와 CFO Jeff Black이 참여하는 동부시간 오전 8:30 컨퍼런스 콜을 진행할 예정입니다.
투자자들은 전화(미국 201-389-0918 또는 국제 +1-877-407-0890) 또는 Exagen 투자자 관계 웹사이트의 웹캐스트 링크를 통해 참여할 수 있습니다. 재청취는 2025년 8월 12일까지 가능하며, 전화로 접속 시 비밀번호 13753132를 사용하거나 회사 웹사이트를 통해 이용할 수 있습니다.
Exagen (NASDAQ : XGN), leader dans les tests auto-immuns, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le 29 juillet 2025, avant l'ouverture des marchés. La société tiendra une conférence téléphonique à 8h30 ET avec le PDG John Aballi et le CFO Jeff Black.
Les investisseurs peuvent se joindre par téléphone (201-389-0918 aux États-Unis ou +1-877-407-0890 à l'international) ou via le lien de la diffusion en direct sur le site des relations investisseurs d'Exagen. Une rediffusion sera disponible jusqu'au 12 août 2025, accessible par téléphone avec le code 13753132 ou via le site web de la société.
Exagen (NASDAQ: XGN), ein führendes Unternehmen im Bereich Autoimmun-Tests, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 29. Juli 2025 vor Börsenöffnung geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz mit CEO John Aballi und CFO Jeff Black abhalten.
Investoren können per Telefon (201-389-0918 in den USA oder +1-877-407-0890 international) oder über den Webcast-Link auf der Investor-Relations-Website von Exagen teilnehmen. Eine Aufzeichnung ist bis zum 12. August 2025 verfügbar und kann telefonisch mit dem Zugangscode 13753132 oder über die Unternehmenswebsite abgerufen werden.
- None.
- None.
CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).
Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.
A replay of the conference call will be available until Tuesday, August 12, 2025. Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13753132. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow @ExagenInc on X.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
When will Exagen (XGN) release Q2 2025 earnings?
How can investors join Exagen's Q2 2025 earnings call?
Who will host Exagen's Q2 2025 earnings call?
Until when will Exagen's Q2 2025 earnings call replay be available?
